Le cluster Radioimmunotherapy (adverse effects) - Thyroid Neoplasms (radiotherapy)
| 000023 (2012) | Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. | |
| 000094 (2006) | Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. | |
| 000160 (1999) | Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. | |
| 000095 (2006) | Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. | |
| 000166 (1999) | Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody. | |
| 000022 (2012) | Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). | |
| 000116 (2005) | Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. | |
| 000125 (2004) | Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans. | |
| 000129 (2003) | Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. | |
| 000139 (2002) | Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. | |
| 000186 (1997) | Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne. | |
| 000199 (1996) | Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. | |
| 000208 (1996) | Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. | |
| 000213 (1995) | Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. | |
| 000254 (1992) | Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation. | |
| 000261 (1992) | Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. |
| This area was generated with Dilib version V0.5.76. |  |